Dobutamine hydrochloride - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for dobutamine hydrochloride and what is the scope of freedom to operate?
Dobutamine hydrochloride
is the generic ingredient in four branded drugs marketed by Baxter Hlthcare, Dr Reddys, Hikma, Hospira, Luitpold, Slate Run Pharma, Teligent, Teva Parenteral, Watson Labs, Watson Labs Inc, and Lilly, and is included in sixteen NDAs. Additional information is available in the individual branded drug profile pages.There are twelve drug master file entries for dobutamine hydrochloride. Six suppliers are listed for this compound.
Summary for dobutamine hydrochloride
| US Patents: | 0 |
| Tradenames: | 4 |
| Applicants: | 11 |
| NDAs: | 16 |
| Drug Master File Entries: | 12 |
| Finished Product Suppliers / Packagers: | 6 |
| Raw Ingredient (Bulk) Api Vendors: | 102 |
| Clinical Trials: | 117 |
| Patent Applications: | 1,083 |
| What excipients (inactive ingredients) are in dobutamine hydrochloride? | dobutamine hydrochloride excipients list |
| DailyMed Link: | dobutamine hydrochloride at DailyMed |
Recent Clinical Trials for dobutamine hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Institutul de Urgenţă pentru Boli Cardiovasculare Prof.Dr. C.C. Iliescu | N/A |
| Koç University | N/A |
| Wuhan Union Hospital, China | Phase 2/Phase 3 |
Pharmacology for dobutamine hydrochloride
| Drug Class | beta-Adrenergic Agonist |
| Mechanism of Action | Adrenergic beta-Agonists |
Medical Subject Heading (MeSH) Categories for dobutamine hydrochloride
Anatomical Therapeutic Chemical (ATC) Classes for dobutamine hydrochloride
US Patents and Regulatory Information for dobutamine hydrochloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospira | DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% | dobutamine hydrochloride | INJECTABLE;INJECTION | 020269-002 | Oct 19, 1993 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Baxter Hlthcare | DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER | dobutamine hydrochloride | INJECTABLE;INJECTION | 020255-001 | Oct 19, 1993 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Hospira | DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER | dobutamine hydrochloride | INJECTABLE;INJECTION | 020201-006 | Jul 7, 1994 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Teligent | DOBUTAMINE HYDROCHLORIDE | dobutamine hydrochloride | INJECTABLE;INJECTION | 074098-001 | Feb 21, 1995 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Watson Labs | DOBUTAMINE HYDROCHLORIDE | dobutamine hydrochloride | INJECTABLE;INJECTION | 074114-001 | Nov 30, 1993 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for dobutamine hydrochloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Lilly | DOBUTREX | dobutamine hydrochloride | INJECTABLE;INJECTION | 017820-002 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
